Amrita Sarkar

Dr. Amrita Sarkar


Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
16 December 2020 in Annals of Vascular Surgery
Verified
Journal Article
Closed access
PDF file
ASAmrita Sarkar
Amrita Sarkar
AJAce St. John
Ace St. John
KNKhanjan H. Nagarsheth
Khanjan H. Nagarsheth

1 May 2019 in International Journal for Parasitology
Verified
Journal Article
Closed access
ASAmrita Sarkar
Amrita Sarkar
NANorma W. Andrews
Norma W. Andrews
MSMaria Fernanda Laranjeira da Silva
Maria Fernanda Laranjeira da Silva

5 December 2022 in Annals of Vascular Surgery
Verified
Journal Article
Closed access
PDF file
ASAmrita Sarkar
Amrita Sarkar
RFRobin Fencel
Robin Fencel
EDEleanor Dunlap
Eleanor Dunlap
SFSuzanna Fitzpatrick
Suzanna Fitzpatrick
KNKhanjan Nagarsheth
Khanjan Nagarsheth

11 November 2025 in Vaccines
Verified
Journal Article
Open access
PDF file
ASAmrita Sarkar
Amrita Sarkar
EREmily P Rabinovich
Emily P Rabinovich
CSCraig Slingluff
Craig Slingluff
Cancer vaccines have emerged as a class of therapeutics designed to harness the immune system to stimulate durable anti-tumor responses with lower systemic toxicity than conventional therapies. Many platforms have been explored, including protein, peptide, DNA, RNA, and cell-based vaccines. Within this landscape, peptide vaccines remain a promising approach. Most clinical trials have examined peripheral immune responses and clinical outcomes, but there is growing interest in the vaccine site microenvironment (VSME) as a window to understand local immune activation and its implications for systemic immunity and tumor control. Studies of the VSME have investigated the effects of adjuvants, local immune cell dynamics, and their correlation with systemic responses and outcomes. Local adjuvants typically enhance immune cell infiltration, though there are concerns regarding VSME sequestration or dysfunction of immune cells, which could impact systemic efficacy. Repeated vaccination at a single site may improve antigen presentation and immune responses, but factors such as injection site location may be linked to variability in clinical outcomes. Current studies are limited by substantial variability in sampling, timing, and analyses used in VSME assessment. This limits the comparability of findings and broader inferences regarding the influence of vaccine site dynamics on therapeutic efficacy. Standardized VSME assessment as part of future vaccine trials may improve evaluation of immune responses and provide a more consistent surrogate for vaccine effectiveness. This refinement may inform optimal vaccine strategies and further support the development of next-generation cancer immunotherapies.

31 December 2022 in Current Surgery Reports
Verified
Journal Article
Closed access
PDF file
ASAmrita Sarkar
Amrita Sarkar
KNKhanjan H. Nagarsheth
Khanjan H. Nagarsheth

1 April 2017 in The FASEB Journal
Verified
Journal Article
Open access
ASAmrita Sarkar
Amrita Sarkar
SSSanket Kumar Shukla
Sanket Kumar Shukla
KSKunal Sikder
Kunal Sikder
Alexander Y. TsygankovAlexander Y. Tsygankov
Alexander Y. Tsygankov
KRKhadija Rafiq
Khadija Rafiq
Objective: Diabetic cardiomyopathy (DCM) is typified by alterations in cardiac morphology and function, independent of hypertension or coronary disease. The disease is characterized by intramyocardial inflammation, cardiomyocytes apoptosis, and cardiac fibrosis, and it can lead to heart failure. The molecular mechanism that links inflammation to DCM is incompletely understood. This study investigates the novel role of allograft inflammatory factor‐1 (AIF‐1) gene expression over the humoral responses during the progression of DCM. Methods and Results: Ten‐week‐old wild type male mice were injected with streptozotocin (50 mg/kg for 5 days intraperitoneally) and studied 8 weeks after induction of diabetes mellitus. Mice with elevated blood glucose levels (> 300 mg/dL) were classified as having diabetes mellitus and DCM was confirmed through ECG. Induction of diabetes resulted in an increase in inflammatory cells. This increase correlated with myocyte death and cardiac contractile dysfunction, indicating a possible role of immune cells in the development of heart failure. We therefore assessed which immune cells were involved in myocyte apoptosis. We found that STZ‐induced diabetes leads to an increase of neutrophil infiltration, which is associated with a decrease of B cell growth and function as well as an increased level of AIF‐1. STZ‐induced diabetes also leads to an increase of interleukin 21 (IL‐21), which is known to induce apoptosis in both resting and activated B cells, followed by a decrease of BCl 2 and BCl‐xL expression. Our data strongly demonstrated that decreased AIF‐1 expression is associated with downregulation of B cells and that AIF‐1 mediates migration of B cell in vitro. Conclusions: Downregulation of the B cell/AIF‐1 interaction leads to myocyte apoptosis and contributes to adverse cardiac remodeling after diabetes induction. These findings point to AIF‐1 as a potential therapeutic target for the maintenance of cardiac function and remodeling during the development of DCM. Support or Funding Information This work was funded by NIH grant for Dr. Khadija Rafiq.